Zentalis Pharmaceuticals Stock Forecast - Simple Exponential Smoothing
| ZNTL Stock | USD 2.94 0.31 9.54% |
Zentalis Stock outlook is based on your current time horizon. Although Zentalis Pharmaceuticals' naive historical forecasting may sometimes provide an important future outlook for the firm, we recommend always cross-verifying it against solid analysis of Zentalis Pharmaceuticals' systematic risk associated with finding meaningful patterns of Zentalis Pharmaceuticals fundamentals over time.
The RSI of Zentalis Pharmaceuticals' stock price is about 62. This usually means that the stock is rather overbought by investors as of now. The main point of the Relative Strength Index (RSI) is to track how fast people are buying or selling Zentalis, making its price go up or down. Momentum 62
Buy Extended
Oversold | Overbought |
EPS Estimate Next Quarter (0.48) | EPS Estimate Current Year (1.76) | EPS Estimate Next Year (1.60) | Wall Street Target Price 5.3125 | EPS Estimate Current Quarter (0.48) |
Using Zentalis Pharmaceuticals hype-based prediction, you can estimate the value of Zentalis Pharmaceuticals Llc from the perspective of Zentalis Pharmaceuticals response to recently generated media hype and the effects of current headlines on its competitors. We also analyze overall investor sentiment towards Zentalis Pharmaceuticals using Zentalis Pharmaceuticals' stock options and short interest. It helps to benchmark the overall future attitude of investors towards Zentalis using crowd psychology based on the activity and movement of Zentalis Pharmaceuticals' stock price.
Zentalis Pharmaceuticals Implied Volatility | 1.42 |
Zentalis Pharmaceuticals' implied volatility exposes the market's sentiment of Zentalis Pharmaceuticals Llc stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Zentalis Pharmaceuticals' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Zentalis Pharmaceuticals stock will not fluctuate a lot when Zentalis Pharmaceuticals' options are near their expiration.
The Simple Exponential Smoothing forecasted value of Zentalis Pharmaceuticals Llc on the next trading day is expected to be 2.94 with a mean absolute deviation of 0.09 and the sum of the absolute errors of 5.61. Zentalis Pharmaceuticals after-hype prediction price | USD 2.94 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Check out Historical Fundamental Analysis of Zentalis Pharmaceuticals to cross-verify your projections. Open Interest Against 2026-04-17 Zentalis Option Contracts
Although open interest is a measure utilized in the options markets, it could be used to forecast Zentalis Pharmaceuticals' spot prices because the number of available contracts in the market changes daily, and new contracts can be created or liquidated at will. Since open interest in Zentalis Pharmaceuticals' options reflects these daily shifts, investors could use the patterns of these changes to develop long and short-term trading strategies for Zentalis Pharmaceuticals stock based on available contracts left at the end of a trading day.
Please note that to derive more accurate forecasting about market movement from the current Zentalis Pharmaceuticals' open interest, investors have to compare it to Zentalis Pharmaceuticals' spot prices. As Ford's stock price increases, high open interest indicates that money is entering the market, and the market is strongly bullish. Conversely, if the price of Zentalis Pharmaceuticals is decreasing and there is high open interest, that is a sign that the bearish trend will continue, and investors may react by taking short positions in Zentalis. So, decreasing or low open interest during a bull market indicates that investors are becoming uncertain of the depth of the bullish trend, and a reversal in sentiment will likely follow.
Zentalis Pharmaceuticals Additional Predictive Modules
Most predictive techniques to examine Zentalis price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Zentalis using various technical indicators. When you analyze Zentalis charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Zentalis Pharmaceuticals Simple Exponential Smoothing Price Forecast For the 27th of January
Given 90 days horizon, the Simple Exponential Smoothing forecasted value of Zentalis Pharmaceuticals Llc on the next trading day is expected to be 2.94 with a mean absolute deviation of 0.09, mean absolute percentage error of 0.03, and the sum of the absolute errors of 5.61.Please note that although there have been many attempts to predict Zentalis Stock prices using its time series forecasting, we generally do not recommend using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Zentalis Pharmaceuticals' next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Zentalis Pharmaceuticals Stock Forecast Pattern
| Backtest Zentalis Pharmaceuticals | Zentalis Pharmaceuticals Price Prediction | Buy or Sell Advice |
Zentalis Pharmaceuticals Forecasted Value
In the context of forecasting Zentalis Pharmaceuticals' Stock value on the next trading day, we examine the predictive performance of the model to find good statistically significant boundaries of downside and upside scenarios. Zentalis Pharmaceuticals' downside and upside margins for the forecasting period are 0.03 and 11.39, respectively. We have considered Zentalis Pharmaceuticals' daily market price to evaluate the above model's predictive performance. Remember, however, there is no scientific proof or empirical evidence that traditional linear or nonlinear forecasting models outperform artificial intelligence and frequency domain models to provide accurate forecasts consistently.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Simple Exponential Smoothing forecasting method's relative quality and the estimations of the prediction error of Zentalis Pharmaceuticals stock data series using in forecasting. Note that when a statistical model is used to represent Zentalis Pharmaceuticals stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | 112.9177 |
| Bias | Arithmetic mean of the errors | -0.0205 |
| MAD | Mean absolute deviation | 0.0935 |
| MAPE | Mean absolute percentage error | 0.0428 |
| SAE | Sum of the absolute errors | 5.61 |
Predictive Modules for Zentalis Pharmaceuticals
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Zentalis Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Zentalis Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Zentalis Pharmaceuticals After-Hype Price Density Analysis
As far as predicting the price of Zentalis Pharmaceuticals at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Zentalis Pharmaceuticals or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Zentalis Pharmaceuticals, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Zentalis Pharmaceuticals Estimiated After-Hype Price Volatility
In the context of predicting Zentalis Pharmaceuticals' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Zentalis Pharmaceuticals' historical news coverage. Zentalis Pharmaceuticals' after-hype downside and upside margins for the prediction period are 0.15 and 11.33, respectively. We have considered Zentalis Pharmaceuticals' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Zentalis Pharmaceuticals is dangerous at this time. Analysis and calculation of next after-hype price of Zentalis Pharmaceuticals is based on 3 months time horizon.
Zentalis Pharmaceuticals Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Zentalis Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Zentalis Pharmaceuticals backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Zentalis Pharmaceuticals, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
1.20 | 8.45 | 0.02 | 0.01 | 9 Events / Month | 6 Events / Month | In about 9 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
2.94 | 2.94 | 0.00 |
|
Zentalis Pharmaceuticals Hype Timeline
Zentalis Pharmaceuticals is at this time traded for 2.94. The entity has historical hype elasticity of 0.02, and average elasticity to hype of competition of -0.01. Zentalis is anticipated not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is over 100%. The immediate return on the next news is anticipated to be very small, whereas the daily expected return is at this time at 1.2%. %. The volatility of related hype on Zentalis Pharmaceuticals is about 120714.29%, with the expected price after the next announcement by competition of 2.93. About 22.0% of the company outstanding shares are owned by insiders. The company has Price to Book (P/B) ratio of 0.75. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. Zentalis Pharmaceuticals recorded a loss per share of 2.08. The entity had not issued any dividends in recent years. Given the investment horizon of 90 days the next anticipated press release will be in about 9 days. Check out Historical Fundamental Analysis of Zentalis Pharmaceuticals to cross-verify your projections.Zentalis Pharmaceuticals Related Hype Analysis
Having access to credible news sources related to Zentalis Pharmaceuticals' direct competition is more important than ever and may enhance your ability to predict Zentalis Pharmaceuticals' future price movements. Getting to know how Zentalis Pharmaceuticals' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Zentalis Pharmaceuticals may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| PLRX | Pliant Therapeutics | (0.32) | 6 per month | 0.00 | (0.09) | 5.47 | (6.71) | 28.96 | |
| ARTV | Artiva Biotherapeutics Common | (0.03) | 4 per month | 7.89 | 0.04 | 10.83 | (11.20) | 118.69 | |
| TIL | Instil Bio | 0.04 | 4 per month | 0.00 | (0.18) | 6.59 | (9.97) | 55.58 | |
| IMMX | Immix Biopharma | (0.39) | 2 per month | 4.35 | 0.15 | 15.04 | (8.41) | 28.79 | |
| STTK | Shattuck Labs | (0.05) | 23 per month | 3.34 | 0.21 | 7.29 | (5.50) | 27.07 | |
| STRO | Sutro Biopharma | 0.54 | 11 per month | 5.37 | 0.08 | 11.76 | (8.62) | 27.28 | |
| ALXO | Alx Oncology Holdings | (0.03) | 8 per month | 0.00 | (0.02) | 12.82 | (9.41) | 27.69 | |
| MGNX | MacroGenics | 0.04 | 4 per month | 3.90 | 0.02 | 6.83 | (6.25) | 26.78 | |
| WHWK | Whitehawk Therapeutics | 0.04 | 6 per month | 4.58 | 0.01 | 6.98 | (7.20) | 21.49 | |
| DTIL | Precision BioSciences | 0.09 | 5 per month | 0.00 | (0.17) | 5.99 | (8.82) | 28.04 |
Other Forecasting Options for Zentalis Pharmaceuticals
For every potential investor in Zentalis, whether a beginner or expert, Zentalis Pharmaceuticals' price movement is the inherent factor that sparks whether it is viable to invest in it or hold it better. Zentalis Stock price charts are filled with many 'noises.' These noises can hugely alter the decision one can make regarding investing in Zentalis. Basic forecasting techniques help filter out the noise by identifying Zentalis Pharmaceuticals' price trends.Zentalis Pharmaceuticals Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Zentalis Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Zentalis Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Zentalis Pharmaceuticals by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
Zentalis Pharmaceuticals Market Strength Events
Market strength indicators help investors to evaluate how Zentalis Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Zentalis Pharmaceuticals shares will generate the highest return on investment. By undertsting and applying Zentalis Pharmaceuticals stock market strength indicators, traders can identify Zentalis Pharmaceuticals Llc entry and exit signals to maximize returns.
Zentalis Pharmaceuticals Risk Indicators
The analysis of Zentalis Pharmaceuticals' basic risk indicators is one of the essential steps in accurately forecasting its future price. The process involves identifying the amount of risk involved in Zentalis Pharmaceuticals' investment and either accepting that risk or mitigating it. Along with some essential techniques for forecasting zentalis stock prices, we also provide a set of basic risk indicators that can assist in the individual investment decision or help in hedging the risk of your existing portfolios.
| Mean Deviation | 4.66 | |||
| Semi Deviation | 3.67 | |||
| Standard Deviation | 8.15 | |||
| Variance | 66.5 | |||
| Downside Variance | 20.09 | |||
| Semi Variance | 13.47 | |||
| Expected Short fall | (6.47) |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Zentalis Pharmaceuticals
The number of cover stories for Zentalis Pharmaceuticals depends on current market conditions and Zentalis Pharmaceuticals' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Zentalis Pharmaceuticals is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Zentalis Pharmaceuticals' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Zentalis Pharmaceuticals Short Properties
Zentalis Pharmaceuticals' future price predictability will typically decrease when Zentalis Pharmaceuticals' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Zentalis Pharmaceuticals Llc often depends not only on the future outlook of the potential Zentalis Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Zentalis Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 71.1 M | |
| Cash And Short Term Investments | 371.1 M |
Check out Historical Fundamental Analysis of Zentalis Pharmaceuticals to cross-verify your projections. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zentalis Pharmaceuticals. If investors know Zentalis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zentalis Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Zentalis Pharmaceuticals is measured differently than its book value, which is the value of Zentalis that is recorded on the company's balance sheet. Investors also form their own opinion of Zentalis Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Zentalis Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zentalis Pharmaceuticals' market value can be influenced by many factors that don't directly affect Zentalis Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zentalis Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zentalis Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zentalis Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.